Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform.
Saved in:
| Title: | Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. |
|---|---|
| Authors: | Ko AH; Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., Kim KP; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Siveke JT; Department of Medical Oncology and Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK/DKFZ, partner site Essen), West German Cancer Center, University Hospital Essen, Essen, Germany., Lopez CD; Division of Hematology Oncology, Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA., Lacy J; Department of Medicine, Section of Medical Oncology, Yale School of Medicine, Yale University, New Haven, CT, USA., O'Reilly EM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Macarulla T; Gastrointestinal Cancer Unit, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Manji GA; Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY, USA., Lee J; Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Ajani J; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Alsina Maqueda M; Gastrointestinal Cancer Unit, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Rha SY; Department of Internal Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea., Lau J; Genentech, Inc., South San Francisco, CA, USA., Al-Sakaff N; F. Hoffmann-La Roche, Ltd, Basel, Switzerland., Allen S; Genentech, Inc., South San Francisco, CA, USA., Lu D; Hoffmann-La Roche Limited, Mississauga, ON, Canada., Shemesh CS; Genentech, Inc., South San Francisco, CA, USA., Gan X; Product Development Safety, Roche (China) Holding Ltd, Shanghai, People's Republic of China., Cha E; Genentech, Inc., South San Francisco, CA, USA., Oh DY; Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.; Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Republic of Korea. |
| Source: | The oncologist [Oncologist] 2023 Jun 02; Vol. 28 (6), pp. 553-e472. |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1549-490X |
|---|---|
| DOI: | 10.1093/oncolo/oyad022 |
